However, efficacy of EGFR antibodies seems to be restricted to patients whose primary tumour is located on the left site of the colon, whilst patients harbouring a tumour situated proximal from the left splenic flexure should rather receive bevacizumab in first line (Arnold et al. 2017). The gene discussed is EGFR; the disease is neoplasm.